KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Non-Current Deffered Revenue: 2013-2019

Historic Non-Current Deffered Revenue for Xenon Pharmaceuticals (XENE) over the last 3 years, with Dec 2019 value amounting to $709,000.

  • Xenon Pharmaceuticals' Non-Current Deffered Revenue was N/A to $709,000 in Q4 2019 from the same period last year, while for Dec 2019 it was $709,000, marking a year-over-year change of. This contributed to the annual value of $709,000 for FY2019, which is N/A change from last year.
  • According to the latest figures from FY2019, Xenon Pharmaceuticals' Non-Current Deffered Revenue is $709,000, which was up 351.59% from $157,000 recorded in FY2014.
  • Xenon Pharmaceuticals' 5-year Non-Current Deffered Revenue high stood at $709,000 for FY2019, and its period low was $709,000 during FY2019.
  • For the 1-year period, Xenon Pharmaceuticals' Non-Current Deffered Revenue averaged around $709,000, with its median value being $709,000 (2019).